.png)
Mid-size Biopharmaceutical
Market Access, HEOR, Medical Affairs
Pre-Launch
Rare Disease
Subscribe to our newsletter to receive the latest case studies.
Mid-size Biopharmaceutical
Market Access, HEOR, Medical Affairs
Pre-Launch
Rare Disease
A mid-size biopharmaceutical company was preparing for the pre-launch of a rare disease therapy with limited comparative data.
At the same time, payers were applying increasing scrutiny to surrogate endpoints and questioning whether they reflected meaningful patient benefit.
The client engaged Alkemi to assess payer perceptions, anticipate objections, and define a pre-launch access and evidence strategy to reduce reimbursement risk.
1. Assessed recent rare disease analogues to understand how payers evaluated surrogate endpoints and value thresholds.
2. Conducted payer and KOL advisory boards to test value messages, assess credibility, and surface anticipated objections.
3. Synthesized findings into clear guidance to strengthen the value narrative and inform pre-launch access planning.
Identify access risk early and align evidence strategy to payer expectations.
"This was exactly what we needed. You helped us see how payers were interpreting the data and gave us a clear path to address it." - Senior Director, Market Access
The client gained clarity on evidence thresholds and decision drivers for reimbursement.
Value messaging was refined to address payer concerns and reduce access risk.
Findings informed both near-term tactics and longer-term evidence generation planning.